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Background and purpose: Chemokines participate in the regulation of immune and inflammatory responses by 
interacting with their receptors, which are primarily expressed on immune and inflammatory cells such as B- and 
T-lymphocytes and antigen-presenting cells. Chemokines and their receptors are therefore considered to mediate 
inflammation and tissue damage in autoimmune disorders. Chemokine receptor (CCR) genotypes were recently 
identified, and the importance of their genetic polymorphisms in some autoimmune and infectious disorders has 
been demonstrated. To define the roles of the polymorphism of the CCR2 gene at codon 64 (CCR2-64I) and the 
32-bp deletion in the coding region of CCR5 (CCR5Δ32) in Korean patients with myasthenia gravis (MG), we 
compared these genotypes in MG cases and healthy controls and investigated the clinical features associated with 
these genotypes.
Methods: One hundred and fifteen healthy controls (51 men and 64 women) and 109 MG patients (44 men and 
65 women) from three University hospitals were included. We examined each patient for clinical features using 
electrophysiology tests, laboratory tests, and thymic pathology. The CCR2-64I and CCR5Δ32 polymorphisms were 
determined by the PCR-RFLP method.
Results: We detected no difference in the frequencies of CCR2-64I polymorphism between MG patients and 
healthy controls. All of the MG patients and the healthy controls were homozygous for the wild-type CCR5 
genotype. The results of electrophysiological tests and thymic pathologies were not influenced by the type of 
CCR2-64I polymorphism. However, the anti-acetylcholine-receptor (AChR) antibody titer was higher in the CCR2 
G/G genotype (13.34±12.71 nmol/L) than in the CCR2 A/A genotype (5.83±2.56 nmol/L).
Conclusions: We found no evidence of an increased risk for MG associated with the CCR2-64I and CCR5Δ32 
polymorphisms. However, the increased anti-AChR antibody titer in the patients with the CCR2 G/G genotype 
suggests that the CCR2 gene play a role in the pathophysiology of MG. 
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INTRODUCTION
Myasthenia gravis (MG) is a T-cell-regulated, anti-
body-mediated autoimmune disorder. Although its 
clinical features and diagnostic methods are fairly 
well established, the underlying genetic factors for 
the elicitation and progression of MG are relatively 
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unknown. A better understanding the molecular and 
cellular mechanisms underlying MG would improve 
disease management and help in the development of 
specific immunotherapies for MG.1 Many studies on 
MG patients have focused on the polymorphisms of 
immunoregulating factors, such as IL-1,2 TNF-α,3 
CTLA-4,4 HLA subtypes,5 IgG receptors,6 the delta- 
subunit of the muscle acetylcholine receptor gene,7 
and AChR epsilon.8 However, the results from these 
studies have been inconsistent, and they have not 
uncovered the etiopathology of MG.
Chemokines are a type of chemoattractant cytokines 
that direct the migration of leukocytes during infla-
mmation and organize their homing into relevant organs.9 
Chemokine receptors (CCRs) are G protein-coupled 
receptors that are primarily expressed on immune and 
inflammatory cells, such as B- and T-lymphocytes and 
antigen-presenting cells.10 Because chemokines and 
their receptors play roles in various inflammatory 
and autoimmune diseases, many investigators have 
focused on the associations between the pathophysiology 
of diseases, chemokines, and CCRs. Recent studies 
on rheumatoid arthritis, asthma,11 experimental auto-
immune encephalomyelitis,12 and multiple sclerosis13 
have all provided evidence supporting such associations. 
Furthermore, some studies have suggested that chemo-
kines or CCRs affect the pathogenesis of MG.1,14 
The G-to-A single-nucleotide polymorphism at position 
190 of the CCR2 gene causes a change from valine 
to isoleucine at codon 64 (CCR2-64I) in the first trans-
membrane region of the protein. A 32-bp deletion in 
the coding region of CCR5 (CCR5Δ32) induces a 
premature stop codon in the third extracellular 
domain of the protein. Both of these polymorphisms 
have been associated with inflammatory diseases. 
The CCR2-64I allelic frequency is lower in patients 
with pulmonary sarcoidosis compared to controls, 
while the frequency of the CCR5Δ32 is significantly 
increased in the same population, suggesting specific 
roles for these polymorphisms in disease protection 
and susceptibility.15 Moreover, the CCR5Δ32 poly-
morphism was associated with multiple sclerosis in 
an HLA-DR4-positive Russian population, suggesting 
that CCR5Δ32 increases the risk of disease develop-
ment.13 Based on these studies, we compared the dis-
tributions of polymorphic variants of these receptors 
in MG patients and aged-matched controls, to determine 
whether the CCR2-64I and CCR5Δ32 polymorphisms 
influence MG susceptibility.
MATERIALS AND METHODS
1. Subjects
One hundred and nine Korean patients (44 men 
and 65 women; mean age±SD=42.8±15.2 years) with 
MG were recruited from three university hospitals 
and signed written informed consents. All patients 
underwent a standard battery of examinations, in-
cluding medical history, physical and neurological 
examinations, and laboratory screening tests (including 
autoimmune screening tests and thyroid function tests). 
The diagnostic criteria for MG were the presence of 
characteristic clinical features with at least one positive 
finding from among the serum anti-AChR antibody 
test, neostigmine test, and repetitive nerve stimulation 
test. The control group consisted of 115 age- and sex- 
matched healthy subjects (51 men and 64 women; 
mean age±SD=43.4±10.0 years) who visited the Health 
Promotion Center of Yongdong Severance hospital 
for regular health checkups. All control subjects signed 
written informed consents and underwent the standard 
battery of laboratory and physical examinations. Control 
subjects with any evidence of neurological diseases 
including MG or autoimmune disease were excluded. 
2. Genetic analysis of CCR polymorphisms
Genomic DNA was isolated from whole blood using 
the QIAmp Blood Kit (Qiagen, Hildren, Germany) as 
described by the manufacturer. The CCR2-64I and 
CCR5Δ32 polymorphisms were genotyped using a 
previously described PCR–RFLP method.10,14
3. Statistical analysis
The frequencies of alleles and genotypes were ob-
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Table 1. Clinical characteristics of the patients with different 
CCR2-64I genotypes
CCR2-64I genotype
p*G/G
(n=61)
G/A
(n=37)
A/A
(n=11)
Initial symptom
Ocular 36 21 7
0.929
Bulbar 3 3 0
Limb 2 1 0
Generalized 17 9 4
Mixed 3 3 0
Diagnostic symptom
Ocular 31 17 5
0.946
Bulbar 2 1 0
Limb 2 1 0
Generalized 21 15 6
Mixed 5 3 0
†MGFA classification
I 28 16 5
0.628
IIA 13 13 5
IIB 10 3 1
IIIA 7 3 0
IIIB 3 2 0
Osserman classification
I 28 16 5
0.569
IIA 23 16 6
IIB 10 4 0
III 0 0 0
IV 0 1 0
*Fisher’s exact test, †MGFA; Myasthenia Gravis Foun-
dation of America.
Table 2. Frequencies of genotypes and alleles of the 
CCR2-64I polymorphism in patients with myasthenia gravis 
and in healthy controls
Patients
(n=109)
Controls
(n=115)
p*
Genotype
G/G  61 (56.0%)  68 (59.1%)
0.387G/A  37 (33.9%)  41 (35.7%)
A/A  11 (10.1%)  6 (5.2%)
Allele
G 159 (72.9%) 177 (76.9%)
0.972
A  59 (27.1%)  53 (23.1%)
*Chi-square test.
tained by direct counting. Pearson’s chi-square test 
was used to determine the statistical significance of 
differences in genotypes and haplotypes between the 
control and patient groups. Pearson’s chi-square test 
was also used to analyze differences in the neurophy-
siological test results (including the repetitive nerve 
stimulation test, neostigmine test, and single-fiber 
EMG), thymic pathologies, and clinical features 
according to the genotypes of the patients. A one- 
way analysis of variance (ANOVA) test was used to 
test for significant differences in the anti-AChR 
antibody titers between patients. Statistical analysis 
was performed using SPSS software (Version 11.0), 
and the cutoff for statistical significance was set at 
p<0.05 (two-sided).
RESULTS
The mean ages at MG onset and diagnosis were 
37.5±17.1 and 38.9±17.1 years, respectively. Ocular 
symptoms (ptosis and diplopia) were most common 
at the initial stage (64 cases, 58.7%) and during the 
diagnostic period (53 cases, 48.6%). The symptoms 
(at the initial and diagnostic periods) and clinical 
classifications (according to the classifications of the 
Myasthenia Gravis Foundation of America and Osser-
man) did not differ significantly with the CCR2-64I 
genotype (Table 1).
The CCR2-64I G/G, G/A, and A/A genotypes 
occurred in 61 (56.0%), 37 (33.9%), and 11 (10.1%) 
MG patients, respectively; in 68 (59.1%), 41 (35.7%), 
and 6 (5.2%) healthy controls (p=0.387). The allele 
frequencies also did not differ between the MG 
patients and the control group (p=0.972) (Table 2). 
For the CCR5Δ32 genotype, all of the MG patients 
and the controls were homozygous for the wild type.  
We performed the repetitive nerve stimulation test 
in 89 patients, the neostigmine test in 53 patients, 
and single-fiber EMG in 40 patients. The results of 
these electrophysiological tests were not influenced 
by the type of CCR2-64I polymorphism (Table 3). 
The anti-AChR antibody titer was measured in 79 
patients, in whom the frequencies of seronegative 
and seropositive patients did not differ with the type 
of CCR2-64I polymorphism. There were no statisti-
cally significant differences between anti-AChR anti-
body titers in patients with the G/G (13.34±12.71  
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Table 3. Diagnostic test results for different CCR2-64I 
genotypes
CCR2-64I genotype
p*
G/G G/A A/A
RNS (n=89)
Negative 13 7 3
0.691
Positive 37 24 5
Neostigmine test (n=53)
Negative 2 1 1
0.067
Positive 29 19 1
SF-EMG (n=40)
Negative 8 4 2
0.876
Positive 17 6 3
Anti-AChR antibody (n=79)
Negative 15 7 2
0.769
Positive 32 20 3
*Fisher’s exact test.
anti-AChR; anti-acetylcholine receptor, RNS; repetitive 
nerve stimulation test, SF-EMG; single-fiber EMG.
nmol/L), G/A (8.18±4.67 nmol/L), and A/A (5.83±2.56 
nmol/L) genotypes (ANOVA, p=0.148). However, 
the anti-AChR antibody titer was higher in patients 
with the G/G genotype than in those with the A/A 
genotype (ANOVA, post-hoc analysis, p=0.038). Among 
48 patients who underwent thymectomy, 15 patients 
exhibited normal pathology, 16 patients had thymic 
hyperplasia, and 17 patients had a thymoma. The thymic 
pathology did not differ with the type of CCR2-64I 
polymorphism (p=0.087).
DISCUSSION
Basic molecular aspects of chemokine biology have 
been found to differ with race.16 While the frequencies 
of the CCR5Δ32 allele are high in northern European 
populations (11~15%), these frequencies are very low 
in Greece, Saudi Arabia, Pakistan, and India (1~3%).17,18 
Furthermore, the CCR5Δ32 allele was not been 
found in China, Japan, Korea, or Thailand.18,19 In 
contrast, the CCR2-64I allele has been found in 
almost all studied populations and is more frequent 
in Africa and Asia than in northern Europe.20 Immi-
gration, genetic admixtures, and the founder effect 
might be responsible for these CCR polymorphic 
differences. The frequency of the CCR2-64I allele in 
our Korean population (25%) is similar to that previously 
reported for Japanese (24%).17 The frequency of the 
CCR5Δ32 polymorphism in the present study is also 
consistent with previous report.19
The relationship between proinflammatory cytokines 
and chemokines in MG can be inferred from previous 
reports. The cytokine, interferon-γ (IFN-γ) significantly 
influences the symptoms and progression of experimental 
autoimmune MG (EAMG), and IFN-γ regulated genes 
are highly expressed in the thymic tissues of MG 
patients.21,22 In addition, IFN-γ and TNF-α both up-
regulate AChR transcripts and thereby contribute to 
the initiation of the autoimmune anti-AChR response.21 
IFN-γ or TNF-α increase the expressions of monocyte 
chemotactic protein-1 (MCP-1) and RANTES (regulated 
on activation, normal T-cell expressed and secreted).23 
MCP-1 is a potent and specific monocyte agonist and 
chemoattractant.24 Mononuclear cells infiltrate thymus 
and skeletal-muscle EAMG, and other studies have also 
shown increased CCR5-positive mononuclear cells in 
chronically inflamed tissues.25,26 Increased MCP-1 pro-
duction may explain the increased leukocyte trafficking 
through muscle following antibody transfer and induction 
of MG symptoms in EAMG.27 It is postulated that 
MCP-1 and RANTES play a central role in those 
cytokine cascade. Because MCP-1 binds to CCR2 and 
RANTES binds to CCR5 with high affinity,24,28 the 
CCR2 and CCR5 polymorphisms might be important 
genetic factors for MG initiation and progression. 
CCR2 is believed to mediate blood monocyte extra-
vasation to sites of inflammation and be involved in 
macrophage recruitment to the injured peripheral 
system.29 The frequency of homozygotes for CCR2- 
64I was found to be lower in sarcoidosis and Alzheimer’s 
disease than in controls, thus indicating that the wild- 
type CCR2 (G/G genotype) could be associated with 
greater inflammation in autoimmune inflammatory 
disease.15,30 Moreover, an animal study has suggested 
that IFN-γ-induced MCP-1 contributes to MG progre-
ssion and that CCR2 is involved in disease progression 
or disease induction.27
In our study, we found no evidence of an increased 
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risk for MG in the genotypes of CCR2-64I polymor-
phism. A previous study also found that the frequencies 
of CCR2 and CCR5 polymorphisms did not differ 
between the MG patients and controls.10 Although 
reports have suggested that CCR2 is involved in disease 
progression,27,29 we found that the clinical features 
and electrophysiological tests in MG patients did not 
differ with the type of CCR2-64I polymorphism. 
Interestingly, the anti-AChR antibody titer was higher 
in the G/G genotype than in the A/A genotype, even 
though the presence of this antibody did not differ 
with the type of CCR2-64I polymorphism. Previous 
studies have suggested that proinflammatory cytokines 
contribute to the initiation of autoimmune anti-AChR 
responses,21 and upregulated MCP-1 production by 
the skeletal muscle was associated with the presence 
of circulating anti-AChR antibodies.27 Although it has 
been widely accepted that antibody titer and disease 
severity or progression in MG are not quantitatively 
related,31 our results support the hypothesis that CCR2 
plays a role in MG pathophysiology via the production 
of anti-AChR antibodies. In MG patients, cytokine 
activity is suggested to initiate the autoimmune anti- 
AChR response.21 Moreover, by upregulating chemokines, 
anti-AChR antibodies may be able to influence the 
severity and course of experimental MG.27 We propose 
that larger studies involving measurements of the 
levels of related cytokines will precisely identify the 
clinical and pathophysiologic relationship between 
CCR2 and anti-AChR antibody. 
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